Business Wire

Regula and Indicio Partner to Transform Identity Verification With Verifiable Credentials

30.7.2025 14:30:00 CEST | Business Wire | Press Release

Share

Regula, a global developer of identity verification (IDV) solutions and forensic devices, enters a strategic technology partnership with Indicio, a market leader in Verifiable Credential technology and decentralized identity solutions. Together, the two companies will deliver a breakthrough in portable digital trust by issuing document and biometric identity verification solutions as tamper-proof Verifiable Credentials.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250730663365/en/

Regula x Indicio: Bridging the gap between physical IDs and tamper-proof digital credentials

This collaboration between Regula and Indicio delivers a holistic infrastructure for creating, storing, and verifying digital identities, underpinned by the most robust verification technologies available today.

After decades of forensic expertise and innovation in document and biometric verification technology, Regula has the most complete set of ID authenticity checks and most trustworthy server-side document NFC verification available in its Regula Document Reader SDK. The solution is backed by Regula’s proprietary world’s largest identity document template database, which currently includes over 15,000 templates of IDs issued in 252 countries and territories.

With Indicio’s field-leading and award-winning decentralized identity technology, the validation of identity documents by Regula can now be transformed into user-held, tamper-proof Verifiable Credentials for instant, seamless verification. This enables both companies to provide the deepest and widest range of globally-interoperable, digital identity solutions for business and governments.

By joining forces, Regula and Indicio could deliver a solution that enables companies to deploy Verifiable Credentials across a wide range of formats, including those specified by the European Union’s Digital Identity Wallet (EUDI), Digital Travel Credentials (DTC) following International Civil Aviation Organization (ICAO) specifications, W3C credentials and the mobile document-mobile driver’s license format (ISO 18013-5, mdoc/mDL).

Indicio will offer their mobile wallet SDK customers Regula’s industry leading biometric and document verification technology to provide the highest level of identity assurance to take a leap forward in the kind of strong, seamless authentication needed for KYC, payments, digital finance, and, of course, travel and hospitality. The combination of Regula and Indicio technology is also capable of tackling the latest challenges in biometric identity fraud and generative AI deepfakes.

“This partnership transforms the way we share and verify data,” said Heather Dahl, CEO of Indicio. “The breadth and depth of Regula’s technology in document authentication is unmatched, and to be able to issue, share, and verify these documents as Verifiable Credentials provide the world with the breakthrough in digital trust it needs. We are tremendously excited to be working with Regula.”

“The global shift towards decentralized digital identity is here today, but it will bring tangible benefits only with the right technology behind it. Our partnership with Indicio bridges the gap between today’s physical documents and tomorrow’s trusted digital credentials. With Regula’s verification capabilities and Indicio’s decentralized infrastructure, organizations now have a powerful way to adopt fully portable digital identity,” says Ihar Kliashchou, Chief Technology Officer at Regula.

To learn more about Regula’s capabilities in supporting Verifiable Credentials, including the DTC specification, visit Regula’s website. To get insights into how DTCs are created and used, read our blog article.

About Indicio

Indicio is a global leader in digital identity, authenticated biometrics, and Verifiable Credential technology with scalable solutions that organizations can rapidly deploy for increased efficiency, better user experience, and reduced cost. Our award-winning enterprise solution, Indicio Proven®, offers the widest range of interoperable decentralized identity options for global deployments, from single sign-on to seamless border crossing as well as compatibility with the European Union’s digital identity and wallet standards.

Learn more about how Indicio is using this technology to successfully transform education, finance, government, health, travel and tourism, and supply chains at indicio.tech.

About Regula

Regula is a global developer of forensic devices and identity verification solutions. With our 30+ years of experience in forensic research and the most comprehensive library of document templates in the world, we create breakthrough technologies for document and biometric verification. Our hardware and software solutions allow over 1,000 organizations and 80 border control authorities globally to provide top-notch client service without compromising safety, security, or speed. Regula has been repeatedly named a Representative Vendor in the Gartner® Market Guide for Identity Verification.

Learn more at www.regulaforensics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250730663365/en/

Contacts

Kristina – ks@regula.us

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye